Clinical trial
Multicenter, Open Label, Phase II Clinical Trial Evaluating the Combination of Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT07901868 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Open Label, Phase II Clinical Trial Evaluating the Combination of Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- PETHEMA Foundation
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- December 31, 2032
- Enrollment
- 60 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
multiple myeloma in relapse, multiple myeloma refractory
Arms
As registered; 2 arms.
-
Negative minimal residual disease at end cycle 12
All participants will receive Elranatamab, Mezigdominde and Dexametahsone in 28-day cycles as follows:
* Oral Mezigdomide: dose of 0.6 mg daily on days 1 to 21 of each cycle (from cycle 2 onwards).
* Oral Dexamethasone: dose of 20 mg/day (≤ 75 years old) or 10 mg/day (\>75 years old) from cycle 1 to 6.
* Subcutaneous Elranatamab:Cycle 1: day1 (step-up dose 12 mg), day4 (step-up dose 32 mg), day8 (target dose 76 mg), day15 (76 mg), and day22 (76 mg).
Cycles 2 and 3: day1 and day15 (76 mg) of each 28-day cycle. From cycle 4 onwards: day1 (76 mg). From Cycle 13 onwards, participants will discontinue elranatamab and will continue with mezigdomide alone.
In those patients who discontinue elranatamab due to sustained MRD negativity, Elranatamab will be reintroduced as from the cycle 2 in case of biological progression (IMWG criteria) or positivization of MRD.
-
Positive minimal residual disease et end cycle 12
All participants will receive Elranatamab, Mezigdominde and Dexametahsone in 28-day cycles as follows:
* Oral Mezigdomide: dose of 0.6 mg daily on days 1 to 21 of each cycle (from cycle 2 onwards).
* Oral Dexamethasone: dose of 20 mg/day (≤ 75 years old) or 10 mg/day (\>75 years old) from cycle 1 to 6.
* Subcutaneous Elranatamab will be given as follows:
* Cycle 1: day1 (step-up dose 12 mg), day4 (step-up dose 32 mg), day8 (target dose 76 mg), day15 (76 mg), and day22 (76 mg).
* Cycles 2 and 3: day1 and day15 (76 mg) of each 28-day cycle.
* From cycle 4 onwards: day1 (76 mg).
* From Cycle 13 onwards, patients with positive minimal residual disease will keep receiving Elranatamab as from cycle 4 plus Mezigdomide with above indicated dose.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of patients achieving minimal residual disease (MRD) negativity.
To evaluate the percentage of participants achieving negative MRD. Negative MRD is defined as the presence of less than 1 tumour cell among 100,000 healthy hematopoietic cells by Next Generation Flow Cytometry in bone marrow, according to the IMWG criteria.
Lead sponsor's other trials
PETHEMA Foundation, most recent start first.
+101 more trials See the organization page
Similar trials
Same condition (Neoplasm, Residual) and phase, most recent start first.
+82 more trials See the condition page